Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
about
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancerLOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival.Cell fate regulation by gelsolin in human gynecologic cancers.Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trialTrabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies.The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.Treatment of recurrent epithelial ovarian cancerAnalysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity.Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test).Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer.Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.The conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells in vitro.Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.Major clinical research advances in gynecologic cancer in 2017.
P2860
Q27853172-D8731C48-D75E-4588-A72D-01D183DBAEE2Q33648465-36C1B5DB-FE2E-4CB7-BE15-E22393BE124CQ33921802-5514AEA4-84C7-47DD-A8AC-9066125B14F8Q34104074-039F14AE-69DD-496E-B24F-369E71093399Q34360216-320D7F5F-5315-4C8D-A735-03533DEB0207Q34407454-F91D2A60-B80F-4D04-B4D1-458D0F440E48Q34413664-8CC796A1-20AC-4348-B9F3-C68687CB1E12Q34413670-41F9D5DA-A7D2-4C63-B93E-E5DF1513F467Q35602185-22A8C50B-0BF3-4CDD-8FAF-294972C494A0Q36063233-63ACAB33-85BF-4DFB-8436-4E184CAB64B1Q36240562-0567D722-6DE9-4900-A43F-6E81B08C20A0Q36671058-D030C7F1-7E16-4905-82DB-80DB6A632A1CQ37224624-7F6DB590-DC6A-4823-B419-175B1D338E9BQ37295702-0B04FBCE-455A-4A25-9DBA-A656A844B2EAQ37669383-3B5BF3A7-4BF5-4FB7-BED1-3B09C3DB7DBFQ42617692-607D8995-68CB-4C08-8CF7-913DE3034388Q43203991-1F9CB4AB-25F3-47B3-899F-D8F8C4D21645Q46611930-85A663D3-D07C-4B5D-AB99-8682D816C41EQ46871150-1A02E9A8-EFF7-489D-A055-CC9E6C76B999Q47134731-40EF9D7B-9EA9-449D-BCC1-FD3E8CF51908Q53730678-2B2399C0-0D1E-4B69-9910-A1EF6507F677Q54952356-4A0E2AB6-51AB-4290-8347-0D600A87BA23
P2860
Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Extending the platinum-free in ...... n in second-line chemotherapy.
@ast
Extending the platinum-free in ...... n in second-line chemotherapy.
@en
type
label
Extending the platinum-free in ...... n in second-line chemotherapy.
@ast
Extending the platinum-free in ...... n in second-line chemotherapy.
@en
prefLabel
Extending the platinum-free in ...... n in second-line chemotherapy.
@ast
Extending the platinum-free in ...... n in second-line chemotherapy.
@en
P1433
P1476
Extending the platinum-free in ...... an in second-line chemotherapy
@en
P2093
Bookman MA
P577
1999-01-01T00:00:00Z